Teodori Laura, Sestili Piero, Madiai Valeria, Coppari Sofia, Fraternale Daniele, Rocchi Marco Bruno Luigi, Ramakrishna Seeram, Albertini Maria Cristina
Diagnostics and Metrology Laboratory, FSN-TECFIS-DIM, ENEA Frascati, Roma, Italy.
Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Front Pharmacol. 2020 Dec 8;11:582003. doi: 10.3389/fphar.2020.582003. eCollection 2020.
Over 313,000 SARS-CoV-2 positive cases have been confirmed in Italy as of 30 September 2020, and the number of deaths exceeding thirty-five thousand makes Italy among the list of most significantly affected countries in the world. Such an enormous occurrence of infections and death raises the urgent demand for effective available treatments. Discovering the cellular/molecular mechanisms of SARS-CoV-2 pathogenicity is of paramount importance to understand how the infection becomes a disease and how to plan any therapeutic approach. In this regard, we performed an analysis to predict the putative virus targets and evidence the already available therapeutics. Literature experimental results identified angiotensin-converting enzyme ACE and Spike proteins particularly involved in COVID-19. Consequently, we investigated the signalling pathways modulated by the two proteins through query miRNet, the platform linking miRNAs, targets, and functions. Our bioinformatics analysis predicted microRNAs (miRs), miR-335-5p and miR-26b-5p, as being modulated by Spike and ACE together with histone deacetylate (HDAC) pathway. Notably, our results identified ACE/ACE2-ATR1-Cholesterol-HDAC axis signals that also matched with some available clinical data. We hypothesize that the current and EMA-approved, SARS-CoV-2 off-label HDAC inhibitors (HDACis) drugs may be repurposed to limit or block host-virus interactions. Moreover, a ranked list of compounds is provided for further evaluation for safety, efficacy, and effectiveness.
截至2020年9月30日,意大利已确诊超过31.3万例新冠病毒阳性病例,死亡人数超过3.5万,这使意大利成为世界上受影响最严重的国家之一。如此大量的感染和死亡事件,引发了对有效可用治疗方法的迫切需求。发现新冠病毒致病性的细胞/分子机制对于理解感染如何演变为疾病以及如何规划任何治疗方法至关重要。在这方面,我们进行了一项分析,以预测假定的病毒靶点并证明现有的治疗方法。文献实验结果表明,血管紧张素转换酶ACE和刺突蛋白与新冠肺炎特别相关。因此,我们通过查询miRNet(连接微小RNA、靶点和功能的平台)研究了这两种蛋白调节的信号通路。我们的生物信息学分析预测,微小RNA(miRs),即miR-335-5p和miR-26b-5p,会受到刺突蛋白和ACE以及组蛋白去乙酰化酶(HDAC)途径的调节。值得注意的是,我们的结果确定了ACE/ACE2-ATR1-胆固醇-HDAC轴信号,这也与一些现有的临床数据相匹配。我们假设,目前已获欧洲药品管理局批准的用于治疗新冠病毒的非标签HDAC抑制剂(HDACis)药物可被重新利用,以限制或阻断宿主与病毒的相互作用。此外,还提供了一份化合物排名清单,以供进一步评估安全性、疗效和有效性。